GENMAB A/S -SP ADR (GMAB) Stock News
NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD
GMAB Latest News, Press Relases and Analysis
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.
Why Genmab Stock Smashed It on Monday
Why Genmab Stock Smashed It on Monday
The company's uterine cancer drug is advancing in its development. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (NASDAQ: GMAB), on the back of encouraging news from the laboratory. The price of those ADRs rose by almost 4% as a result -- quite a distance higher than the S&P 500's (SNPINDEX: ^GSPC) 0.4% advance.
Investors eye May jobs report and Trump tariff updates: What to know this week
Investors will be watching for updates on the labor market and President Trump's trade war as markets turn the page on a historically strong May.
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 to June 3 in Chicago. Key highlights include the first public results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate […]
CrowdStrike Strengthens AI Security with NVIDIA Enterprise AI Factory Integration
On May 19, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced its integration into the NVIDIA Enterprise AI Factory validated design, enabling enterprises to protect AI infrastructure, systems, and models as they scale AI adoption. With NVIDIA Blackwell infrastructure, this validated design provides a full-stack AI ecosystem—covering data ingestion, model training, deployment, and runtime use—to help businesses harness […]
GMAB or RGEN: Which Is the Better Value Stock Right Now?
GMAB vs. RGEN: Which Stock Is the Better Value Option?
Mentions: RGEN
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at whereGenmab A/S (NASDAQ:GMAB) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining […]
Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Royalty Pharma Plc (NASDAQ:RPRX) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade […]
Curtiss-Wright Corporation (CW): Among Stocks Insiders Were Buying In Q1 2025
We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where Curtiss-Wright Corporation (NYSE:CW) stands against other stocks insiders were buying in Q1 2025. About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while […]
Is Mastercard (MA) The Most Expensive Stock Insiders Are Dumping In March?
We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Mastercard Incorporated (NYSE:MA) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market index […]
